Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Operating Income: 2020-2025

Historic Operating Income for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to $90.2 million.

  • Pharming Group N.V's Operating Income rose 2096.11% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.8 million, marking a year-over-year increase of 442.95%. This contributed to the annual value of -$8.6 million for FY2024, which is 60.03% down from last year.
  • Latest data reveals that Pharming Group N.V reported Operating Income of $90.2 million as of Q3 2025, which was up 2,270.99% from $3.8 million recorded in Q2 2025.
  • Pharming Group N.V's Operating Income's 5-year high stood at $90.2 million during Q3 2025, with a 5-year trough of -$19.4 million in Q2 2024.
  • For the 3-year period, Pharming Group N.V's Operating Income averaged around $5.0 million, with its median value being $1.5 million (2023).
  • As far as peak fluctuations go, Pharming Group N.V's Operating Income spiked by 44,862.60% in 2022, and later crashed by 584.96% in 2023.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Operating Income stood at $13.5 million in 2021, then plummeted by 175.13% to -$10.2 million in 2022, then skyrocketed by 110.50% to $1.1 million in 2023, then soared by 527.13% to $6.7 million in 2024, then soared by 2,096.11% to $90.2 million in 2025.
  • Its Operating Income stands at $90.2 million for Q3 2025, versus $3.8 million for Q2 2025 and $6.7 million for Q4 2024.